Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman for Johnson & Johnson Medical Devices Group, to its Board of Directors

FORT LAUDERDALE, FL–(Marketwired – December 12, 2017) – Motus GI Holdings, Inc., (“Motus” or the “Company”), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Gary J. Pruden to its Board of Directors. Mr. Pruden most recently served as Executive Vice President and Worldwide Chairman for the Johnson & Johnson (“J&J”) (NYSE: JNJ) Medical Devices group.

Over the course of his 32-year career at J&J, Mr. Pruden held numerous senior leadership positions across both the medical devices and pharmaceutical sectors. As the Worldwide Chairman of the Medical Device group, he led a global business where new technologies, global expansion and focus on the patient were keys to success.

“We are thrilled to welcome someone of Gary’s caliber to the Motus Board of Directors and believe his wealth of experience and expertise will be an important asset to the Company. Gary brings to our Board a deep understanding of the healthcare system as well as the commercialization of new opportunities on a global basis, as witnessed throughout his distinguished career at J&J,” said Mark Pomeranz, CEO of Motus GI. “In the near-term we remain focused on developing and executing our clinical market development strategy for the Pure-Vu® System in the U.S. We believe Gary’s input and guidance will be invaluable at this important phase of growth for Motus. Gary’s knowledge nicely complements the other members of Motus’ board, all of whom will play an integral part in achieving our goal of securing sustainable long-term growth and ultimately driving significant value for our shareholders.”

During his career at J&J, Mr. Pruden led a large global business with a significant portion of sales coming from outside of the United States including a strong focus on emerging markets. He has a broad background in technology and pharmaceutical innovation and has been involved in numerous M&A transactions at J&J. Mr. Pruden also helped lead the J&J strategic collaboration with Google that was established for the advancement of surgical robotics. He has extensive experience in portfolio management including two large divestitures (Cordis Corporation and Codman Neurosurgery) and exits of non-strategic businesses, quality and compliance, as well as global regulatory experience. Mr. Pruden earned his bachelor’s degree in finance from Rider University and served on the Board of Trustees of Rider University from 2011-2015.

“I am delighted to be joining the Motus team at such an exciting time in the Company’s development. I believe that the Pure-Vu System’s ability to cleanse the colon during a colonoscopy will play a significant role in improving outcomes, reducing costs and enhancing experiences, which ultimately should help to reduce the risk of colorectal cancer and other GI disorders. I look forward to leveraging my expertise and working closely with the other members of the Motus Board and Management team to further develop the Company’s strategy to make a significant difference in this large market with over 30 million colonoscopies worldwide,” said Mr. Pruden.

About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The Pure-Vu® System has the potential to improve the colonoscopy experience for physicians, patients and payers by diminishing the dependency on pre-procedural preparations, thereby enhancing the quality and cost-effectiveness of the exam. For more information, visit

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company’s product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475